Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

SARTORIUS STEDIM BIOTECH

(DIM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
304.8(c) 302.2(c) 297(c) 282.4(c) 282(c) Last
68 524 57 813 50 797 108 886 69 191 Volume
+0.79% -0.85% -1.72% -4.92% -0.14% Change
More quotes
Financials
Sales 2020 1 878 M 2 239 M 2 239 M
Net income 2020 342 M 407 M 407 M
Net Debt 2020 261 M 311 M 311 M
P/E ratio 2020 75,8x
Yield 2020 0,33%
Sales 2021 2 273 M 2 711 M 2 711 M
Net income 2021 418 M 498 M 498 M
Net Debt 2021 199 M 237 M 237 M
P/E ratio 2021 61,6x
Yield 2021 0,41%
Capitalization 25 995 M 30 957 M 30 994 M
EV / Sales 2020 14,0x
EV / Sales 2021 11,5x
Nbr of Employees 6 979
Free-Float 25,7%
More Financials
Company
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and... 
More about the company
Notations Surperformance© of Sartorius Stedim Biotech
Trading Rating : Investor Rating :
More Ratings
All news about SARTORIUS STEDIM BIOTECH
11/02SARTORIUS STEDIM BIOTECH : closes acquisition of BIA Separations
PR
11/02SARTORIUS STEDIM BIOTECH SA : Notification of transactions made by persons disch..
EQ
10/31SARTORIUS STEDIM BIOTECH : Monthly statement on outstanding equity shares and vo..
CO
10/20SARTORIUS STEDIM BIOTECH : Conference Call 9M|2020 Presentation
PU
10/20SARTORIUS STEDIM BIOTECH : Earnings Release 9M|2020
PU
10/20SARTORIUS STEDIM BIOTECH : Strong profitable growth at Sartorius Stedim Biotech
PU
10/20SARTORIUS STEDIM BIOTECH : Strong profitable growth at Sartorius
PU
10/20SARTORIUS STEDIM BIOTECH : Strong profitable growth at Sartorius Stedim Biotech
PR
10/20SARTORIUS STEDIM BIOTECH : Press Release
CO
10/20SARTORIUS STEDIM BIOTECH : 3rd quarter results
CO
10/15SARTORIUS STEDIM BIOTECH : quaterly earnings release
10/02SARTORIUS STEDIM BIOTECH : Purification specialist BIA Separations to become par..
PU
10/02SARTORIUS STEDIM BIOTECH : Purification specialist BIA Separations to become par..
PU
09/30SARTORIUS STEDIM BIOTECH : Monthly statement on outstanding equity shares and vo..
CO
09/25SARTORIUS VORZUEGE : Receives a Buy rating from JP Morgan
MD
More news
News in other languages on SARTORIUS STEDIM BIOTECH
11/16Des idées d'ETF pour miser sur le retour en grâce des valeurs moyennes
11/03SARTORIUS STEDIM BIOTECH : Notifications des transactions (02.11.2020)
11/02SARTORIUS STEDIM BIOTECH SA : Notification des transactions effectuées par les p..
10/2320 valeurs de croissance cotées en Europe
10/23AVIS D'ANALYSTES DU JOUR : Air France-KLM, BioMérieux, Logitech, Michelin, Nestl..
More news
Analyst Recommendations on SARTORIUS STEDIM BIOTECH
More recommendations
Stock Trading Strategies
SARTORIUS STEDIM BIOTECH - 11/09
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Chart SARTORIUS STEDIM BIOTECH
Duration : Period :
Sartorius Stedim Biotech Technical Analysis Chart | DIM | FR0013154002 | MarketScreener
Technical analysis trends SARTORIUS STEDIM BIOTECH
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 289,63 €
Last Close Price 282,00 €
Spread / Highest target 37,6%
Spread / Average Target 2,70%
Spread / Lowest Target -31,6%
EPS Revisions
Managers
NameTitle
Joachim Kreuzburg Chairman & Chief Executive Officer
Volker Niebel Executive VP-Operations & Information Technology
Oscar-Werner Reif Executive VP-Research & Development
Henri Riey Independent Non-Executive Director
Anne-Marie Graffin Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS STEDIM BIOTECH90.93%30 957
ABBOTT LABORATORIES22.51%190 724
MEDTRONIC PLC-0.12%152 963
BECTON, DICKINSON AND COMPANY-16.36%66 464
HOYA CORPORATION29.62%46 912
BAXTER INTERNATIONAL INC.-9.84%38 838